1. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities
- Author
-
Cynthia Osborne, Shripad Sinari, Cristi L Aitelli, Tracy M. Moses, Angela Baker, Jennifer Dinh, Bodour Salhia, Joanne L. Blum, Ahmet Kurdoglu, Julie Koeman, Jessica Aldrich, Catalin Barbacioru, Jeff Kiefer, Spyro Mousses, David Craig, John D. Carpten, Jeffrey M. Trent, Alexis Christoforides, Onur Sakarya, Joyce O'Shaughnessy, Shukmei Wong, Linh Hoang, Asim Siddiqui, Tyler Izatt, Francisco M. De La Vega, Anthony W. Tolcher, Daniel D. Von Hoff, and Paul Billings
- Subjects
Adult ,Cancer Research ,Receptor, ErbB-2 ,DNA Mutational Analysis ,Gene Expression ,Breast Neoplasms ,medicine.disease_cause ,Transcriptome ,Breast cancer ,medicine ,PTEN ,Humans ,HRAS ,Molecular Targeted Therapy ,Prospective Studies ,Neoplasm Metastasis ,Gene ,Triple-negative breast cancer ,Sequence Deletion ,biology ,Genome, Human ,Sequence Analysis, RNA ,Forkhead Box Protein M1 ,Cancer ,High-Throughput Nucleotide Sequencing ,Forkhead Transcription Factors ,Middle Aged ,medicine.disease ,Treatment Outcome ,Oncology ,Receptors, Estrogen ,Cancer research ,biology.protein ,Female ,KRAS ,Tumor Suppressor Protein p53 ,Receptors, Progesterone ,Chromosomes, Human, Pair 7 ,alpha Catenin ,Genes, Neoplasm ,Genome-Wide Association Study ,Signal Transduction - Abstract
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2. Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor prognosis with median survival of one year. Here, we present initial analyses of whole genome and transcriptome sequencing data from 14 prospective mTNBC. We have cataloged the collection of somatic genomic alterations in these advanced tumors, particularly those that may inform targeted therapies. Genes mutated in multiple tumors included TP53, LRP1B, HERC1, CDH5, RB1, and NF1. Notable genes involved in focal structural events were CTNNA1, PTEN, FBXW7, BRCA2, WT1, FGFR1, KRAS, HRAS, ARAF, BRAF, and PGCP. Homozygous deletion of CTNNA1 was detected in 2 of 6 African Americans. RNA sequencing revealed consistent overexpression of the FOXM1 gene when tumor gene expression was compared with nonmalignant breast samples. Using an outlier analysis of gene expression comparing one cancer with all the others, we detected expression patterns unique to each patient's tumor. Integrative DNA/RNA analysis provided evidence for deregulation of mutated genes, including the monoallelic expression of TP53 mutations. Finally, molecular alterations in several cancers supported targeted therapeutic intervention on clinical trials with known inhibitors, particularly for alterations in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways. In conclusion, whole genome and transcriptome profiling of mTNBC have provided insights into somatic events occurring in this difficult to treat cancer. These genomic data have guided patients to investigational treatment trials and provide hypotheses for future trials in this irremediable cancer. Mol Cancer Ther; 12(1); 104–16. ©2012 AACR.
- Published
- 2012